Treatment patterns, effectiveness, and patient-reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective real-world study.

Lesang ShenJun ZhouYi-Ding ChenJinhua DingHaiyan WeiJian LiuWenjie XiaBojian XieXiaohong XieXujun LiYuechu DaiGuobing ZhangXia QiuChao LiShanshan SunWuzhen ChenDihe GongHengyu LiJian HuangXia JiangChao Ni

Published in: Cancer medicine (2022)

Palbociclib is effective for front-line use and for treating endocrine-sensitive patients in real-world China and is generally well tolerated. The prevalence of AEs in the Chinese population is different from that reported in the PALOMA-2/3 trials.

Keyphrases

patient reported outcomes
end stage renal disease
ejection fraction
newly diagnosed
randomized controlled trial
systematic review
chronic kidney disease
risk factors
peritoneal dialysis
metastatic breast cancer
clinical trial
stem cells
cross sectional
bone marrow
combination therapy